Inotropic Therapy for Heart Failure
Author:
- Lynne Warner StevensonLSLynne Warner Stevenson
- 17 December 1998
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 339 (25) , 1848-1850
Abstract
Looking back reveals how the direction of therapy for heart failure has changed since the inception of the first large clinical trial of vesnarinone, an inotropic agent, in April 1990. At that time, many investigators remained interested in the concept of heart failure as a defect that could be remedied by drugs that enhanced cardiac contractility.1 Intravenous dopamine and dobutamine were widely used to increase cardiac output with less chronotropy and fewer arrhythmias than the more potent adrenergic agonists isoproterenol, epinephrine, and norepinephrine. Even though excess mortality was found with long-term outpatient infusions of dobutamine and the oral sympathomimetic amines . . .Keywords
This publication has 15 references indexed in Scilit:
- A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart FailureNew England Journal of Medicine, 1998
- The Effect of Digoxin on Mortality and Morbidity in Patients with Heart FailureNew England Journal of Medicine, 1997
- Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).Circulation, 1993
- The Search for the Ideal Positive Inotropic AgentNew England Journal of Medicine, 1993
- Effects of Vesnarinone on Morbidity and Mortality in Patients with Heart FailureNew England Journal of Medicine, 1993
- Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group.Circulation, 1992
- Effect of Oral Milrinone on Mortality in Severe Chronic Heart FailureNew England Journal of Medicine, 1991
- I. IntroductionJACC, 1988
- New Positive Inotropic Agents in the Treatment of Congestive Heart FailureNew England Journal of Medicine, 1986
- Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure.Circulation, 1984